Prognostic Value of Neurotrophic Factors and Neuron Specific Elonase in Patients with Extracerebral Brain Tumors

The aim of the investigation was to study the content of brain-derived neurotrophic factor (BDNF), glial-derived neurotrophic factor (GDNF) and neuron specific enolase (NSE) in patients with mature brain tumors before and after surgery and assess their prognostic value.

Materials and Methods. The study involved 39 women. Group 1 consisted of 16 virtually healthy subjects, group 2 — 23 patients with mature brain tumors, among them there were 10 patients with pituitary adenoma and 13 — with meningiomas. The examination of the patients included clinical and neurological examination, determination of BDNF, GDNF (R&D Systems, USA) and NSE (Vector Best, Russia) content in blood plasma using enzyme immunoassay (EIA) performed 5 days before the surgery, 5 days and 6 months after extracerebral oncotomy. There were also carried out pathomorphological study of postoperative material, neuro-imaging study.

Results. Mean BDNF level in blood plasma of patients was significantly higher than in healthy subjects. The comparative assessment of the content of neurotrophic factors in groups of patients with various tumor types showed that before surgical treatment there was the tendency for higher mean GDNF level in patients with meningiomas compared to those with pituitary adenomas, though the difference was not significant. The patients with the subsequent (6 months after surgical removal of mature brain tumor) recurrence were found to have higher

BDNF concentrations in blood plasma 5 days after surgery than the patients who had no continued tumor growth in first 6 months after the operation. The patients with continued tumor growth appeared to have imbalance in the dynamics of postoperative BDNF and GDNF levels.

Conclusion. BDNF concentration increase in blood plasma in the nearest time after surgical removal of a mature extracerebral brain tumor has unfavorable prognostic value in relation to the high probability of tumor recurrence in the subsequent 6 months.

1. Krylov V.V. Lektsii po neyrokhirurgii [Lectures on Neurosurgery]. Moscow: KMK; 2008; 280 p.
2. Fantacci C., Capozzi D., Ferrara P., Chiaretti A. Neuroprotective role of nerve growth factor in hypoxic-ischemic brain injury. Brain Sci 2013; 3(3): 1013–1022.
3. Binder D.K., Scharfman H.E. Brain-derived neurotrophic factor. Growth Factors 2004 Sep; 22(3): 123–131, http://dx.doi.org/10.1080/08977190410001723308.
4. Artico M., Bianchi E., Magliulo G., De Vincentiis M., De Santis E., Orlandi A., Santoro A., Pastore F.S., Giangaspero F., Caruso R., Re M., Fumagalli L. Neurotrophins, their receptors and KI-67 in human GH-secreting pituitary adenomas: an immunohistochemical analysis. Int J Immunopathol Pharmacol 2012 Jan–Mar; 25(1): 117–125.
5. Artico M., Bronzetti E., Pompili E., Ionta B., Alicino V., D’Ambrosio A., Santoro A., Pastore F.S., Elenkov I., Fumagalli L. Immunohistochemical profile of neurotrophins in human cranial dura mater and meningiomas. Oncology Reports 2009 Jun; 21(6): 1373–1380, http://dx.doi.org/10.3892/or_00000363.
6. Klein A.B., Williamson R., Santini M.A., Clemmensen C., Ettrup A., Rios M., Knudsen G.M., Aznar S. Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol 2011 Apr; 14(3): 347–353, http://dx.doi.org/10.1017/S1461145710000738.
7. Yan Chen. Effects of glial cell line-derived neurotrophic factor (GDNF) on stem/progenitor cell proliferation and differentiation. Abstract of dissertation. UKnowledge; 2005; р. 233.
8. Wang X., Liao Z.G., Liu M. GDNF expression following the severe brain injury in rats. Fa Yi Xue Za Zhi 2003; 19(1): 1–3.
9. Airaksinen M.S., Saarma M. The GDNF family: signaling, biological functions and therapeutic value. Nat Rev Neurosci 2002 May; 3(5): 383–394.
10. Japón M.A., Urbano A.G., Sáez C., Segura D.I., Cerro A.L., Diéguez C., Alvarez C.V. Glial-derived neurotropic factor and RET gene expression in normal human anterior pituitary cell types and in pituitary tumors. J Clin Endocrinol Metab 2002 Apr; 87(4): 1879–1884, http://dx.doi.org/10.1210/jcem.87.4.8383.
11. Ahmed F., Gyorgy A., Kamnaksh A., Ling G., Tong L., Parks S., Agoston D. Time-dependent changes of protein biomarker levels in the cerebrospinal fluid after blast traumatic brain injury. Electrophoresis 2012 Dec; 33(24): 3705–3711, http://dx.doi.org/10.1002/elps.201200299.
12. Singh H.V., Pandey A., Shrivastava A.K., Raizada A., Singh S.K., Singh N. Prognostic value of neuron specific enolase and IL-10 in ischemic stroke and its correlation with degree of neurological deficit. Clin Chim Acta 2013 Apr 18; 419: 136–138, http://dx.doi.org/10.1016/j.cca.2013.02.014.
13. Patapoutian A., Reichardt L.F. Trk receptors: mediators of neurotrophin action. Curr Opin Neurobiol 2001 Jun; 11(3): 272–280, http://dx.doi.org/10.1016/S0959-4388(00)00208-7.
14. Sakharnova T.A., Vedunova M.V., Mukhina I.V. Brain-derived neurotrophic factor (BDNF) and its role in central nervous system functioning. Neirokhimiya 2012; 24(4): 269–277.
15. Elkabes S., DiCicco-Bloom E.M., Black I.B. Brain microglia/macrophages express neurotrophins that selectively regulate microglial proliferation and function. J Neurosci 1996 Apr 15; 16(8): 2508–2521.
16. Pascual A., Hidalgo-Figueroa M., Gómez-Díaz R., López-Barneo J. GDNF and protection of adult central catecholaminergic neurons. J Mol Endocrinol 2011 Jun 8; 46(3): R83–R92, http://dx.doi.org/10.1530/JME-10-0125.
17. Saavedra A., Baltazar G., Duarte E.P. Driving GDNF expression: the green and the red traffic lights. Prog Neurobiol 2008 Nov; 86(3): 186–215, http://dx.doi.org/10.1016/j.pneurobio.2008.09.006.
18. Airaksinen M.S., Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 2002 May; 3(5): 383–394.

Kurakina А.S., Vedunova М.V., Stchelchkova N.А., Grigorieva V.N., Mukhina I.V. Prognostic Value of Neurotrophic Factors and Neuron Specific Elonase in Patients with Extracerebral Brain Tumors. Sovremennye tehnologii v medicine 2014; 6(3): 6